Grifols, S.A.
GRFSAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JP Morgan | maintain | Neutral | Oct 26, 2026 |
| JP Morgan | maintain | Neutral | Dec 8, 2025 |
| JP Morgan | maintain | Neutral | Jun 17, 2025 |
| Deutsche Bank | downgrade | Hold →Sell | Mar 12, 2024 |
| JP Morgan | maintain | Neutral | Dec 5, 2023 |
| Deutsche Bank | downgrade | Buy →Hold | Nov 5, 2021 |
| Credit Suisse | upgrade | Neutral →Outperform | Mar 23, 2021 |
| HSBC | upgrade | Hold →Buy | Mar 11, 2021 |
| Santander | upgrade | Hold →Buy | Oct 28, 2019 |
| JP Morgan | upgrade | Neutral →Overweight | Jun 27, 2019 |
| Berenberg | downgrade | Buy →Hold | Feb 8, 2019 |
| Morgan Stanley | maintain | Underweight | Jan 2, 2019 |
| Morgan Stanley | maintain | Underweight | Oct 1, 2018 |
| Morgan Stanley | maintain | Underweight | Mar 1, 2018 |
| Nomura | maintain | Buy | Mar 17, 2016 |
| Berenberg | upgrade | Hold →Buy | Feb 9, 2016 |
| Morgan Stanley | downgrade | Equal Weight →Underweight | Jan 4, 2016 |
| HSBC | downgrade | Buy →Hold | Dec 2, 2015 |
| Berenberg | downgrade | Buy →Hold | Nov 20, 2015 |
| Morgan Stanley | downgrade | Overweight →Equal Weight | Feb 12, 2015 |
| JP Morgan | upgrade | Neutral →Overweight | Mar 4, 2014 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $0.33| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 2, 2026 | $0.34 | $0.32 | $2.28B | $2.21B |
| Jul 28, 2026 | $0.25 | $0.27 | $2.13B | $2.17B |
| May 7, 2026 | $0.17 | $0.16 | $2.00B | $2.03B |
| Feb 26, 2026 | $0.29 | $0.29 | $2.34B | $2.34B |
| Nov 4, 2025 | $0.21 | $0.24 | $2.14B | $2.15B |
| Jul 29, 2025 | $0.19 | $0.23 | $2.17B | $2.20B |
| May 12, 2025 | $0.13 | $0.15 | $1.99B | $1.96B |
| Feb 26, 2025 | $0.24 | $0.23 | $2.06B | $2.03B |
News
Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up 10%, net profit up 28%, and leverage now below 4x. Strategic expansion into Egypt is expected to diversify plasma sourcing, reduce costs, and support margin improvement through geographic diversification.
Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript
Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.
Grifols, S.A. (NASDAQ: GRFS - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 7,001,241 shares, a growth of 105.0% from the September 15th total of 3,414,455 shares. Based on an average daily volume of 808,104 shares, the days-to-cover ratio is
Grifols (NASDAQ: GRFS - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. Earnings and Valuation This table compares Grifols and
Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?
Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.
Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.
Gilead Sciences (NASDAQ: GILD - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 83.7% of Gilead Sciences shares
Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with …